Mitral regurgitation epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(30 intermediate revisions by 11 users not shown)
Line 1: Line 1:
__NOTOC__
{| class="infobox" style="float:right;"
|-
| [[File:Siren.gif|30px|link=Mitral regurgitation resident survival guide]]|| <br> || <br>
| [[Mitral regurgitation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']]
|}
{{Mitral regurgitation}}
{{Mitral regurgitation}}
{{CMG}}; '''Associate Editors-In-Chief:''' [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S.
{{CMG}}; {{AE}} [[Varun Kumar]], M.B.B.S., [[Lakshmi Gopalakrishnan]], M.B.B.S., {{Rim}}


==Epidemiology and Demographics==
==Overview==
The incidence of mitral regurgitation is approximately 2% of the population. Mitral regurgitation affects both males and females equally <ref>[http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/mitral-valve-disease/ The Cleveland Clinic Center for Continuing Education > Mitral Valve Disease: Stenosis and Regurgitation] Authors: Ronan J. Curtin and Brian P. Griffin. Retrieved September 2010</ref>. Mitral regurgitation is one of the two most common valvular heart disease in the elderly, and is the most common form of valvular insufficiency <ref name=uptodate>[http://www.uptodate.com/patients/content/topic.do?topicKey=~PxxZxAzdJkaEgaZ Valvular heart disease in elderly adults] Authors: Dania Mohty, Maurice Enriquez-Sarano. Section Editors:Catherine M Otto, Kenneth E Schmader. Deputy Editor: Susan B Yeon. This topic last updated: April 20, 2007. Last literature review version 18.2: May 2010</ref>. Among patients over the age of 55, 20% will have mitral regurgitation. The most common cause in the developed world is [[mitral valve prolapse]] and in the developing world is [[rheumatic heart disease]].
Mitral regurgitation (MR) is one of the most common [[valvular disease]]s in the general population, ranking first among valvular regurgitation abnormailities. The prevalence of MR of a severity equal to or more than mild was reported in The Framingham Heart Study as 19.0% in men and 19.1% in women.  The prevalence of MR increases with age.
 
==Prevalence==
 
* The Framingham Heart Study, a prospective epidemiologic study, evaluated the [[prevalence]] and severity of MR and other valvular diseases by color [[Doppler]] examinations in 1,696 men and 1,893 women.
* The study revealed that MR is the most common valvular regurgitation in the general population, followed by [[tricuspid regurgitation]] and then [[aortic regurgitation]].
* The prevalence of MR (with a severity ranging from trace to ≥ moderate regurgitation) was 87.7% in men and 91.5% in women.
* When trace regurgitation is excluded, the prevalence of MR of a severity ≥ mild was 19.0% in men and 19.1% in women.
* The elevated prevalence of trace regurgitation can be a normal finding related to an artifact or an anatomic characteristic of the closure of the [[mitral valve]].<ref name="pmid10190406">{{cite journal| author=Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al.| title=Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) | journal=Am J Cardiol | year= 1999 | volume= 83 | issue= 6 | pages= 897-902 | pmid=10190406 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10190406  }} </ref><ref name="pmid101904062">{{cite journal| author=Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al.| title=Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) | journal=Am J Cardiol | year= 1999 | volume= 83 | issue= 6 | pages= 897-902 | pmid=10190406 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10190406  }}</ref>
 
==Age==
 
* The prevalence of MR increases with age. MR is one of the most common valvular heart disease in the elderly.
* Shown below are tables depicting the prevalence of MR by age and severity in men and women according the results of the Framingham Heart Study.<ref name="pmid10190406">{{cite journal| author=Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al.| title=Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) | journal=Am J Cardiol | year= 1999 | volume= 83 | issue= 6 | pages= 897-902 | pmid=10190406 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10190406  }} </ref>
 
{|
|-
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''Severity of MR''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center colspan= 5|'''Prevalence of MR by age in men'''
|-
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''26-29''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''40-49''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''50-59''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''60-69''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''70-83'''
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''No MR (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |14.4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |13.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |11.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |12.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |9.0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''Trace (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |76.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |72.9 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |74.6 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |60.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |51.7
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''Mild (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |8.9 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | 13.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |12.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |24.6 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |28.1
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''Moderate or severe (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1.6 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |2.4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |11.2
|}
 
 
 
{|
|-
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''Severity of MR''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center colspan=5|'''Prevalence of MR by age in women'''
|-
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center|  || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''26-29''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''40-49''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''50-59''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center | '''60-69''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''70-83'''
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''No MR (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |14.0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |8.6 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |9.0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |7.2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |5.6
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | '''Trace (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |76.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |75 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |74 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |66.5  || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |70.8
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Mild (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |9.7 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |15.5 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |16 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |24 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |23.6
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Moderate or severe (%)''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.9 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |2.3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0
|}
 
==Gender==
 
* Overall, mitral regurgitation affects both males and females equally. However, there are some minor differences when age is considered.


==References==
==References==
Line 10: Line 65:
[[Category:Valvular heart disease]]
[[Category:Valvular heart disease]]
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Disease]]
[[Category:Cardiac surgery]]
[[Category:Cardiac surgery]]
[[Category:Surgery]]
[[Category:Surgery]]
[[Category:Overview complete]]
[[Category:Overview complete]]
[[Category:Template complete]]
[[Category:Disease state]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 15:59, 18 December 2019
Resident
Survival
Guide

Mitral Regurgitation Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Mitral Regurgitation from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

Stages

History and Symptoms

Physical Examination

Chest X Ray

Electrocardiogram

Echocardiography

Cardiac MRI

Cardiac Catheterization

Treatment

Overview

Acute Mitral Regurgitation Treatment

Chronic Mitral Regurgitation Treatment

Surgery

Follow Up

Case Studies

Case #1

Mitral regurgitation epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mitral regurgitation epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onMitral regurgitation epidemiology and demographics

CDC on Mitral regurgitation epidemiology and demographics

Mitral regurgitation epidemiology and demographics in the news

Blogs on Mitral regurgitation epidemiology and demographics

Directions to Hospitals Treating Mitral regurgitation

Risk calculators and risk factors for Mitral regurgitation epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S., Lakshmi Gopalakrishnan, M.B.B.S., Rim Halaby, M.D. [2]

Overview

Mitral regurgitation (MR) is one of the most common valvular diseases in the general population, ranking first among valvular regurgitation abnormailities. The prevalence of MR of a severity equal to or more than mild was reported in The Framingham Heart Study as 19.0% in men and 19.1% in women. The prevalence of MR increases with age.

Prevalence

  • The Framingham Heart Study, a prospective epidemiologic study, evaluated the prevalence and severity of MR and other valvular diseases by color Doppler examinations in 1,696 men and 1,893 women.
  • The study revealed that MR is the most common valvular regurgitation in the general population, followed by tricuspid regurgitation and then aortic regurgitation.
  • The prevalence of MR (with a severity ranging from trace to ≥ moderate regurgitation) was 87.7% in men and 91.5% in women.
  • When trace regurgitation is excluded, the prevalence of MR of a severity ≥ mild was 19.0% in men and 19.1% in women.
  • The elevated prevalence of trace regurgitation can be a normal finding related to an artifact or an anatomic characteristic of the closure of the mitral valve.[1][2]

Age

  • The prevalence of MR increases with age. MR is one of the most common valvular heart disease in the elderly.
  • Shown below are tables depicting the prevalence of MR by age and severity in men and women according the results of the Framingham Heart Study.[1]
Severity of MR Prevalence of MR by age in men
26-29 40-49 50-59 60-69 70-83
No MR (%) 14.4 13.3 11.3 12.7 9.0
Trace (%) 76.7 72.9 74.6 60.3 51.7
Mild (%) 8.9 13.5 12.5 24.6 28.1
Moderate or severe (%) 0 0.3 1.6 2.4 11.2


Severity of MR Prevalence of MR by age in women
26-29 40-49 50-59 60-69 70-83
No MR (%) 14.0 8.6 9.0 7.2 5.6
Trace (%) 76.3 75 74 66.5 70.8
Mild (%) 9.7 15.5 16 24 23.6
Moderate or severe (%) 0 0.9 1 2.3 0

Gender

  • Overall, mitral regurgitation affects both males and females equally. However, there are some minor differences when age is considered.

References

  1. ↑ 1.0 1.1 Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL; et al. (1999). "Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)". Am J Cardiol. 83 (6): 897–902. PMID 10190406.
  2. ↑ Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL; et al. (1999). "Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)". Am J Cardiol. 83 (6): 897–902. PMID 10190406.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Mitral_regurgitation_epidemiology_and_demographics&oldid=1592213"